Development, characterization and humanization of NCI-N87 human gastric carcinoma xenograft model in NSG mice

AACR-NCI-EORTC 2025 -- NCI-N87, a human gastric adenocarcinoma cell line, is widely used for gastric cancer and epithelial research, due to its clinically relevant properties such as gastric drug permeability and resistance, tumor suppressor genetic mutations, and overexpression of HER2. The anti-HER2 antibody trastuzumab, and HER2-targeting antibody-drug conjugate (ADC) trastuzumab deruxtecan (DXd), are approved treatments for gastric cancer. To generate a well-characterized model of gastric cancer for the testing of various therapeutics modalities, NCI-N87 was established in vitro and in vivo. Standard of care therapies and experimental ADCs were tested in vitro and in vivo, and tumor growth and antibody efficacy in the presence of PBMC humanization was explored.